German biotechnology company Molecular Health and Italy-based Axxam have entered a strategic partnership to enhance the discovery of advanced drug targets.
The collaboration aims to provide biopharmaceutical companies with precise, clinically driven solutions.
It integrates Molecular Health’s AI-driven Dataome platform with Axxam’s DiscoveryMAXX process to advance the identification and validation of novel therapeutic targets.
Dataome is a digital drug development platform that curates and structures molecular, phenotypic, and clinical data from various datasets, improving drug development.
Molecular Health is known for its AI-driven development solutions, and Axxam provides integrated early discovery services.
The two companies plan to leverage their combined expertise to deliver disease-to-target and target-to-lead solutions.
Axxam CEO Ciriaco Maraschiello said: “Identifying the right target is one of the most critical and challenging steps in drug discovery. At Axxam, we believe that biology-driven validation is key to translating digital assessments and predictions into real-world therapies.
“This strategic partnership between a biology powerhouse like Axxam and a precision medicine-focused AI company like Molecular Health is enabling a new level of accuracy and efficiency in the early drug discovery process, allowing our clients to make more informed decisions, faster, in both preclinical and clinical development.”
Molecular Health analyses complex datasets by applying advanced AI technologies to identify high-potential drug targets.
The computational predictions will be integrated into Axxam’s discovery platform, which boasts decades of experience in biology, assay development, and compound profiling.
The integration aims to simplify the discovery for the pharmaceutical and biotech industries.
The partnership will see AI-derived targets undergo rigorous experimental validation using advanced in-vitro technologies, including induced pluripotent stem cell (iPSC)-based models.
It ensures the biological and disease relevance of the targets, enhancing their translational value for drug development.
By bridging AI-powered clinical-molecular predictions with biological insights, Molecular Health and Axxam are set to deliver next-generation discovery programmes.
Molecular Health CEO Friedrich von Bohlen said: “Understanding molecular causalities and variants in phenotypes, diseases and endotypes is essential for pharma and biotech companies to improve efficiency and success rates in drug development.
“The integration of our data/AI-based knowledge, simulations and predictions with Axxam’s preclinical biology and chemistry assays and expertise will offer improved and accelerated outcomes in early drug discovery.
“This will enable our joint clients to gain deeper insights, enhance decision-making, and expand their options for drug discovery and clinical development programmes.”
